CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2006; 56:282-291
doi: 10.3322/canjclin.56.5.282
© 2006 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Staging Soft Tissue Sarcoma: Evolution and Change
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kotilingam, D.
Right arrow Articles by Pollock, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotilingam, D.
Right arrow Articles by Pollock, R. E.

Staging Soft Tissue Sarcoma

Evolution and Change

Dhanasekaran Kotilingam, MBBS, Dina Chelouche Lev, MD, Alexander J. F. Lazar, MD, PhD and Raphael E. Pollock, MD, PhD

Dr. Kotilingam is Graduate Research Assistant, The University of TexasMD Anderson Cancer Center, Houston, TX.
Dr. Lev is Assistant Professor in Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Dr. Lazar is Assistant Professor in Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dr. Pollock is Division Head, Surgery; Professor, Surgical Oncology; Professor, Molecular and Cellular Oncology; Chair, Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

This article is available online at http://CAonline.AmCancerSoc.org

Soft tissue sarcoma (STS) is an extremely heterogeneous group of rare tumors that share a putative mesenchymal cell origin. STS can occur in any soft tissue in the body, yet all share a common feature of primarily disseminating hematogenously, particularly to the lungs. Staging for STS is particularly useful in prognosis, design of effective multimodality treatment programs, and comparing treatment outcomes from different centers and different eras. The current iteration of AJCC STS staging includes Tumor, Grade, Node, and Metastasis with "a" indicating superficial and "b" indicating deep designations. Further opportunities to improve this process exist, particularly as molecular considerations become more apparent, and future evolution into an even more useful STS staging system can be anticipated.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Hajitou, D. C. Lev, J. A. F. Hannay, B. Korchin, F. I. Staquicini, S. Soghomonyan, M. M. Alauddin, R. S. Benjamin, R. E. Pollock, J. G. Gelovani, et al.
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging
PNAS, March 18, 2008; 105(11): 4471 - 4476.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by American Cancer Society.